Liquidia Co. (NASDAQ:LQDA) General Counsel Russell Schundler Sells 1,063 Shares

Liquidia Co. (NASDAQ:LQDA) General Counsel Russell Schundler sold 1,063 shares of Liquidia stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $11.51, for a total value of $12,235.13. Following the completion of the transaction, the general counsel now owns 487,328 shares in the company, valued at $5,609,145.28. The trade was a 0.22 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Russell Schundler also recently made the following trade(s):

• On Monday, October 14th, Russell Schundler sold 2,576 shares of Liquidia stock. The stock was sold at an average price of $11.11, for a total transaction of $28,619.36.

Liquidia Trading Up 0.3 %

Shares of LQDA opened at $11.26 on Wednesday. Liquidia Co. has a 52 week low of $6.83 and a 52 week high of $16.99. The firm has a market cap of $953.05 million, a price-to-earnings ratio of -6.91 and a beta of 0.22. The stock has a 50 day moving average of $10.78 and a 200-day moving average of $11.33.

Analysts Set New Price Targets

LQDA has been the subject of several recent research reports. Bank of America dropped their price objective on shares of Liquidia from $24.00 to $23.00 and set a “buy” rating for the company in a research report on Tuesday, August 20th. BTIG Research dropped their target price on Liquidia from $29.00 to $25.00 and set a “buy” rating on the stock in a report on Monday, August 19th. Lifesci Capital started coverage on Liquidia in a report on Thursday, October 3rd. They issued an “outperform” rating and a $30.00 price target for the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $19.00 price objective on shares of Liquidia in a research report on Thursday, November 14th. Finally, Scotiabank started coverage on shares of Liquidia in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $30.00 price objective for the company. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, six have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $24.00.

Institutional Trading of Liquidia

A number of institutional investors and hedge funds have recently modified their holdings of the business. Whitefort Capital Management LP boosted its holdings in shares of Liquidia by 119.8% in the 3rd quarter. Whitefort Capital Management LP now owns 1,702,025 shares of the company’s stock valued at $17,020,000 after buying an additional 927,546 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in Liquidia by 144.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 390,257 shares of the company’s stock valued at $3,903,000 after acquiring an additional 230,820 shares during the period. Anson Funds Management LP acquired a new position in Liquidia in the third quarter valued at approximately $1,764,000. Sapient Capital LLC bought a new position in shares of Liquidia during the third quarter valued at approximately $1,336,000. Finally, BNP Paribas Financial Markets raised its position in shares of Liquidia by 735.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 140,190 shares of the company’s stock worth $1,402,000 after purchasing an additional 123,402 shares during the period. 64.54% of the stock is owned by institutional investors and hedge funds.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).